Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.07 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The observational study will be carried out in two stages. At the first stage, the efficacy and safety of Aprotinin intravenous infusion as add-on therapy to the standard of care will be studied. At the second stage, two groups will be included: the first group will be the inhaled Aprotinin add-on therapy, the second group will be intravenous Aprotinin in combination with Favipiravir.
Description: Time to two negative PCR tests with at least 24 hours interval [days]
Measure: Time to elimination of SARS-CoV-2 virus Time: 10 daysDescription: Time to CRP <10 mg/L [days]
Measure: Time to CRP normalization Time: 10 daysDescription: Time to D-dimer <243 ng/mL [days]
Measure: Time to D-dimer normalization Time: 10 daysDescription: Time to body temperature <37oC [days]
Measure: Time to body temperature normalization Time: 14 daysDescription: Change of ANC [cells/L]
Measure: Change in absolute neutrophil count (ANC) Time: Baseline to Day 14Description: Change of WBC [cells/L]
Measure: Change in white blood cells (WBC) Time: Baseline to Day 14Description: Change of CRP [mg/L]
Measure: Change of CRP Time: Baseline to Day 14Description: Change of D-dimer [ng/mL]
Measure: Change of D-dimer Time: Baseline to Day 14Description: Change of fibrinogen [g/L]
Measure: Change in fibrinogen Time: Baseline to Day 14Description: Change of Quick's value [%]
Measure: Change of Quick's value Time: Baseline to Day 14Description: Change of INR [score]
Measure: Change of international normalized ratio (INR) Time: Baseline to Day 14Description: Improvement, no change or worsening of the lung injury on CT scan [proportion of patients]
Measure: Changes of lung injury on CT scan Time: Baseline to Day 14Description: Frequency of clinical status improvement by 2 scores in accordance with the WHO-OSCI or discharge from the hospital [proportion of patients]
Measure: Frequency of clinical status improvement by 2 scores in accordance with the WHO-OSCI or discharge from the hospital Time: 14 daysDescription: Frequency of transfer to the ICU, non-invasive ventilation, invasive ventilation and mortality rate [proportion of patients]
Measure: Frequency of deterioration of the patients' status Time: 14 daysDescription: Frequency of AEs and SAEs of various severity according to subjective complains, physical examination, vital signs, laboratory tests and ECG [% of patients]
Measure: Frequency of AEs and SAEs Time: 14 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports